By broadening in vivo and cell line studies across this new pharmacologic scaffold, these studies add to the growing evidence implicating PI3K/mTOR inhibition as a viable strategy in MYCN-driven pediatric cancers including both neuroblastoma and medulloblastoma. This evidence concerns the gene MYCN and medulloblastoma.